Skip to content
Roboearth – Lifestyle
Author:
NurExone Biologic Inc
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
NurExone Announces Closing of Non-Brokered Private Placement
June 30, 2026
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
June 24, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
June 1, 2026
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
May 19, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
May 14, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
April 27, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 16, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
April 1, 2026
1
2
Next Page
→